Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.

by Lisa G M van Baarsen, Saskia Vosslamber, Marianne Tijssen, Josefien M C Baggen, Laura F van der Voort, Joep Killestein, Tineke C T M van der Pouw Kraan, Chris H Polman, Cornelis L Verweij
Published 2008-04-01

In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma

by Bas D. Koster, Tamarah D. de Jong, Mari F. C. M. van den Hout, Berbel J. R. Sluijter, Ronald J. C. L. M. Vuylsteke, Barbara G. Molenkamp, Saskia Vosslamber, M. Petrousjka van den Tol, Alfons J. M. van den Eertwegh, Tanja D. de Gruijl
Published 2020-01-01

T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A+CD141+ cDC1 and CD14+ antigen-presenting cell recruitment

by Tanja D de Gruijl, M Petrousjka van den Tol, Bas D Koster, Rik J Scheper, Barbara G Molenkamp, Alfons JM van den Eertwegh, Mari FCM van den Hout, Berbel JR Sluijter, Paul AM van Leeuwen, Marta López González, Annelies W Turksma, Saskia Vosslamber, Ekaterina J Jordanova
Published 2021-03-01